Competitive ELISA Protocol

Competitive ELISA๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

Competitive ELISA ๋ถ„์„์€ ์ƒ˜ํ”Œ ๋‚ด ๋ถ„์„๋ฌผ์˜ ์–‘์„ ์ธก์ •ํ•˜๊ฑฐ๋‚˜ ๋‹ค๋ฅธ ์กฐ๊ฑด๋“ค์—์„œ ๋ถ„์„๋ฌผ ์–‘์˜ ๋ณ€ํ™”๋ฅผ ์ธก์ •ํ•˜๋Š”๋ฐ ์ด์šฉ๋ฉ๋‹ˆ๋‹ค. Competitive ELISA ๋ถ„์„์€ ์ƒ˜ํ”Œ ๋‚ด ๋‹ค์–‘ํ•œ ๋Œ€์‚ฌ์ฒด, ํ˜ธ๋ฅด๋ชฌ ๋ฐ ๋‹จ๋ฐฑ์งˆ์„ ํšจ๊ณผ์ /์ •๋Ÿ‰์ /๊ฒฝ์ œ์ ์œผ๋กœ ์ธก์ •ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. Sandwich ELISA์™€ ์œ ์‚ฌํ•˜๊ฒŒ, competitive ELISA๋Š” ์ผ์ฐจ ํ•ญ์ฒด ๋ฐ ํšจ์†Œ์™€ ์—ฐ๊ฒฐ๋œ ์ด์ฐจํ•ญ์ฒด๋ฅผ ์ด์šฉํ•˜์—ฌ ์ƒ˜ํ”Œ๋‚ด ๋ถ„์„๋ฌผ์˜ ์–‘์„ ์ธก์ •ํ•ฉ๋‹ˆ๋‹ค.

๊ทธ๋ฆผ 1: ELISA plate์— ๊ณ ์ •๋œ ๋ถ„์„๋ฌผ์— ์ผ์ฐจํ•ญ์ฒด๊ฐ€ ๊ฒฐํ•ฉํ•˜๋Š” Competitive ELISA์˜ ์›๋ฆฌ ๊ฐœ๋žต๋„. ํšจ์†Œ์™€ ๊ฒฐํ•ฉ๋œ ๊ฒ€์ถœ ์ด์ฐจํ•ญ์ฒด(enzyme-lined detection secondary antibody)๊ฐ€ ๊ฒฐํ•ฉํ•ญ์ฒด(capture antibody)์™€ ๊ฒฐํ•ฉํ•œ๋‹ค.

Competitive ELISA ๋ถ„์„์˜ ์žฅ์  ๋ฐ ๋‹จ์ 

Competitive ELISA ๋ถ„์„์€ ์ฝ”๋ฅดํ‹ฐ์†”(Cortisol), T3, ํ•˜์ด๋“œ๋ก์‹œํ”„๋กค๋ฆฐ(hydroxyproline), ์„ธ๋กœํ† ๋‹Œ(serotonin) ๊ณผ ๊ฐ™์€ ๋‹ค์–‘ํ•œ ํ˜ธ๋ฅด๋ชฌ ๋ฐ ์‹ ํ˜ธ๋ฌผ์งˆ(signalling molecules)์„ ๋ถ„์„ํ•˜๋Š”๋ฐ ํ›Œ๋ฅญํ•œ ๋„๊ตฌ์ž…๋‹ˆ๋‹ค. Competitive ELISA๋Š” ๊ณ ๊ฐ€์˜ ์žฅ๋น„๋ฅผ ์‚ฌ์šฉํ•˜์ง€ ์•Š๊ณ ๋„, ๋ถ„์„๋ฌผ์„ ์ธก์ •ํ•  ์ˆ˜ ์žˆ๋Š” ์ €๋ ดํ•˜๊ณ  ํšจ๊ณผ์ ์ด๋ฉฐ ๋น ๋ฅธ ์—ฐ๊ตฌ๋ฐฉ๋ฒ•์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

์žฅ์ 

  • ๋ณตํ•ฉ์  ์ƒ˜ํ”Œ ๋‚ด์˜ ๋ถ„์„๋ฌผ ์ธก์ •: competitive ELISA๋ถ„์„์˜ ์žฅ์ ์€ ๋ณตํ•ฉ์ ์ธ ์ƒ๋ฌผํ•™์  ์ƒ˜ํ”Œ ๋‚ด์— ์žˆ๋Š” ๊ด€์‹ฌ ๋ถ„์„๋ฌผ์„ ๋ถ„์„ํ•  ์ˆ˜ ์žˆ๋Š” ๋Šฅ๋ ฅ์— ์žˆ์Šต๋‹ˆ๋‹ค. ๋ถ„์„๊ณผ์ •์—์„œ ๊ฒฐํ•ฉํ•ญ์ฒด(capture antibody)์™€ ์ƒ˜ํ”Œ์„ ํ˜ผํ•ฉํ•˜๋Š”๋ฐ, ์ด๋Š” ํšจ๊ณผ์ ์œผ๋กœ ๊ฒฐํ•ฉํ•ญ์ฒด-๋ถ„์„๋ฌผ ๋ณตํ•ฉ์ฒด(the capture-analyte complex)๋ฅผ์ƒ์„ฑํ•˜๋„๋ก ํ•ด์ค๋‹ˆ๋‹ค.

๋‹จ์ 

  • Negative controls์—์„œ ์–‘์„ฑ ๊ฒฐ๊ณผ๊ฐ€ ๋„์ถœ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค: well์ด ์ œ๋Œ€๋กœ ์ฐจ๋‹จ๋˜์ง€ ์•Š์•˜์„ ๊ฒฝ์šฐ, ํ•ญ์›์ด๋‚˜ ์ด์ฐจํ•ญ์ฒด๊ฐ€ well์— ๋น„ํŠน์ด์  ๊ฒฐํ•ฉ์„ ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

 

  • ์‹œ๊ทธ๋„์ด ์ƒ˜ํ”Œ ๋‚ด ํ•ญ์›์˜ ์–‘๊ณผ ๋ฐ˜๋น„๋ก€ํ•ฉ๋‹ˆ๋‹ค: ํ•ญ์›์ด ๊ณ ๋†๋„๋กœ ํฌํ•จ๋œ ์ƒ˜ํ”Œ์˜ ๊ฒฝ์šฐ, ์•ฝํ•œ ์‹ ํ˜ธ๊ฐ€ ์ƒ์„ฑ๋˜๊ณ  ๋ถ„์„ ๋ฒ”์œ„์— ์˜ํ–ฅ์„ ์ค„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ ์ ˆํ•œ ๋†๋„ ๋ฒ”์œ„์—์„œ ์ธก์ •ํ•˜๊ธฐ ์œ„ํ•ด ์ƒ˜ํ”Œ์˜ ํฌ์„ ๊ณผ์ •์ด ํ•„์š”ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Competitive ELISA ํ‘œ์ค€๊ณก์„ 

Competitive ELISA ๋ถ„์„์€ ํฌํšํ•ญ์ฒด(capture antibody)๊ฐ€ ์ƒ˜ํ”Œ ๋‚ด์˜ ํ•ญ์›๊ณผ ๊ฒฝ์Ÿํ•˜๋Š” ์›๋ฆฌ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ํ•ฉ๋‹ˆ๋‹ค. ์ฒซ์งธ๋กœ, ํ‘œ์ง€ ๋˜์ง€ ์•Š์€ ๊ฒฐํ•ฉํ•ญ์ฒด(unlabeled capture antibody)๊ฐ€ ๋ถ„์„ํ•˜๊ณ ์ž ํ•˜๋Š” ํ•ญ์›์„ ํฌํ•จํ•œ ์ƒ˜ํ”Œ๊ณผ ํ•จ๊ป˜ ๋ฐฐ์–‘๋ฉ๋‹ˆ๋‹ค. ์ด๋•Œ ํ•ญ์ฒด-ํ•ญ์› ๋ณตํ•ฉ์ฒด๊ฐ€ ํ˜•์„ฑ๋ฉ๋‹ˆ๋‹ค. ์ด ๊ณผ์ •์—์„œ ๊ณผ์ž‰์˜ ํ•ญ์ฒด๊ฐ€ ๊ฐ€ํ•ด์ง€๊ณ , ๊ฒฐ๊ณผ์ ์œผ๋กœ ๋ฐฐ์–‘ ๊ณผ์ • ํ›„์— ๊ฒฐํ•ฉํ•˜์ง€ ์•Š์€ ํ•ญ์ฒด(free antibody)๊ฐ€ ๋‚จ๊ฒŒ ๋ฉ๋‹ˆ๋‹ค.

๋‹ค์Œ ๋‹จ๊ณ„์—์„œ, ๋ถ„์„ํ•˜๊ณ ์ž ํ•˜๋Š” ํ•ญ์›(inhibitor antigen)์ด ๋ฏธ๋ฆฌ ์ฝ”ํŒ…๋œ ELISA plate์— ํ•ญ์ฒด-ํ•ญ์› ๋ณตํ•ฉ์ฒด๋ฅผ ๊ฐ€ํ•ฉ๋‹ˆ๋‹ค. ์ฒซ๋ฒˆ์งธ ๋‹จ๊ณ„์—์„œ๊ฒฐํ•ฉํ•˜์ง€ ์•Š๊ณ  ๋‚จ์€ํ•ญ์ฒด๊ฐ€ plate์— ์žˆ๋Š” inhibitor antigen์— ๊ฒฐํ•ฉํ•˜๊ฒŒ ๋ฉ๋‹ˆ๋‹ค. ๋ฏธ๋ฆฌ ์ƒ์„ฑ๋œ ํ•ญ์ฒด-ํ•ญ์› ๋ณตํ•ฉ์ฒด๋Š” ๋‹ค์Œ ์„ธ์ฒ™๋‹จ๊ณ„์—์„œ ์ œ๊ฑฐ๋ฉ๋‹ˆ๋‹ค.

๋‹ค์Œ์œผ๋กœ, ํšจ์†Œ์™€ ๊ฒฐํ•ฉ๋œ ๊ฒ€์ถœํ•ญ์ฒด(enzyme-linked detection antibody)๋ฅผ plate์— ๊ฐ€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” inhibitor antigen์— ๊ฒฐํ•ฉ๋œ ์ผ์ฐจํ•ญ์ฒด์— ๊ฒฐํ•ฉํ•˜๊ฒŒ ๋ฉ๋‹ˆ๋‹ค. ๋งˆ์ง€๋ง‰์œผ๋กœ, ๊ธฐ์งˆ(substrate)๋ฅผ ๊ฐ€ํ•˜๋ฉด ๋น„์ƒ‰๋ณ€ํ™”๊ฐ€ ์ผ์–ด๋‚ฉ๋‹ˆ๋‹ค. ์‹ ํ˜ธ์˜ ์„ธ๊ธฐ๋Š” ์ƒ˜ํ”Œ ๋‚ด์˜ ํ•ญ์›์˜ ์–‘๊ณผ ๋ฐ˜๋น„๋ก€ํ•˜์—ฌ ๋‚˜ํƒ€๋‚ฉ๋‹ˆ๋‹ค.

๊ทธ๋ฆผ 2: Competitive ELISA ํ‘œ์ค€๊ณก์„ . ์ƒ˜ํ”Œ ๋‚ด ๋ถ„์„๋ฌผ์˜ ์–‘์€ ํก๊ด‘๋„์— ๋ฐ˜๋น„๋ก€ํ•˜๋Š”๋ฐ, ์ด๋Š” ๋ณตํ•ฉ์ฒด ํ˜•์„ฑ ๋‹จ๊ณ„์—์„œ ํฌํšํ•ญ์ฒด์™€ ํ•ญ์›์ด ๊ฒฐํ•ฉํ•˜๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค.

์•„๋ž˜์˜ ํ”„๋กœํ† ์ฝœ์€ Competitive ELISA kit์„ ์œ„ํ•œ ์˜ˆ์‹œ์ž…๋‹ˆ๋‹ค. Competitive ELISA kits์€ ์ƒ˜ํ”Œ ๋‚ด ๋ถ„์„๋ฌผ์˜ ๊ฒ€์ถœ ๋ฐ ์ •๋Ÿ‰ํ™”๋ฅผ ๊ฐ€๋Šฅํ•˜๊ฒŒ ํ•ฉ๋‹ˆ๋‹ค. ์ด๋ฅผ ํ†ตํ•ด ์—ฐ๊ตฌ์ž๋“ค์€ ์ƒ˜ํ”Œ ์•ˆ์˜ ๋ถ„์„๋ฌผ์˜ ์–‘์„ ๊ณ„์‚ฐํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ด๋Š” ๋‹จ๋ฐฑ์งˆ ๋†๋„ ์ฆ๊ฐ€, ๋‹จ๋ฐฑ์งˆ์˜ ์ธ์‚ฐํ™”(phosphorylation) ๋˜๋Š” ๋‹จ๋ฐฑ์งˆ ๋†๋„์˜ ๊ฐ์†Œ๋ฅผ ์ธก์ •ํ•˜๋Š”๋ฐ ๋งค์šฐ ์œ ์šฉํ•ฉ๋‹ˆ๋‹ค.

Competitive ELISA ๋‹จ๊ณ„๋ณ„ ํ”„๋กœํ† ์ฝœ

๊ทธ๋ฆผ 3: Competitive ELISA ํ”„๋กœํ† ์ฝœ

์ˆœ์„œ ๊ณผ์ •

1

ํ‘œ์ค€๋ฌผ์งˆ, ์‹คํ—˜ํ•  ์ƒ˜ํ”Œ ๋ฐ control์„ pre-coated plate์˜ well์— ๋„ฃ๊ณ , ๊ฐ ์œ„์น˜๋ฅผ ๊ธฐ๋กํ•œ๋‹ค. ๊ฐ ํ‘œ์ค€๋ฌผ์งˆ๊ณผ ์ƒ˜ํ”Œ์€ ์ด์ค‘์œผ๋กœ ์ธก์ •ํ•˜๋Š” ๊ฒƒ์ด ๊ถŒ์žฅ๋œ๋‹ค. ํ‘œ์ค€๋ฌผ์งˆ, ์ƒ˜ํ”Œ ๋ฐ control์„ ๊ฐ€ํ•˜๊ธฐ ์ „์— plate๋ฅผ 2ํšŒ ์„ธ์ฒ™ํ•œ๋‹ค.

2

์ƒ˜ํ”Œ๊ณผ biotin-detection antibody๋ฅผ ๊ฐ€ํ•œ๋‹ค: ํ‘œ์ค€๋ฌผ์งˆ, blank (sample/standard dilution buffer) ๋˜๋Š” ์ƒ˜ํ”Œ์„50µl ๊ฐ€ํ•œ๋‹ค. Blank well์—๋Š” sample/standard dilution buffer์„ ๊ฐ€ํ•œ๋‹ค. ์ฆ‰์‹œ biotin-detection antibody working solution์„ ๊ฐ well์— ๊ฐ€ํ•œ๋‹ค. ์ œ๊ณต๋œ Plate sealer๋กœ ํ”Œ๋ ˆ์ดํŠธ๋ฅผ ๋ฎ์€ ํ›„, ์กฐ์‹ฌ์Šค๋Ÿฝ๊ฒŒ ํ†กํ†ก ๋‘๋“œ๋ ค ์ž˜ ์„ž์ด๋„๋ก ํ•œ๋‹ค. 37°C์—์„œ 45๋ถ„๊ฐ„ ๋ฐฐ์–‘ํ•œ๋‹ค. (์šฉ์•ก์„ ๊ฐ€ํ•  ๋•Œ๋Š” plate ๋ฒฝ์— ๋‹ฟ๊ฑฐ๋‚˜ ๊ฑฐํ’ˆ์ด ์ƒ๊ธฐ์ง€ ์•Š๋„๋ก, micro ELISA plate well์˜ ๋ฐ”๋‹ฅ์— ๊ฐ€ํ•œ๋‹ค)

3

์„ธ์ฒ™: ๊ฐ well์„ ํก์ธํ•˜๊ณ  ์„ธ์ฒ™ํ•œ๋‹ค. ์„ค๋ช…์„œ์— ๋”ฐ๋ผ ์ด ๊ณผ์ •์„ 3ํšŒ ๋ฐ˜๋ณตํ•œ๋‹ค.

4

HRP-Streptavidin Conjugate (SABC): 100µl์˜ SABC working solution์„ ๊ฐ well์— ๋„ฃ์–ด์ค€๋‹ค. ์ƒˆ๋กœ์šด plate sealer๋กœ ๋ฎ๋Š”๋‹ค. 37°C์—์„œ 30๋ถ„๊ฐ„ ๋ฐฐ์–‘ํ•œ๋‹ค.

5

์„ธ์ฒ™: ์„ค๋ช…์„œ์— ๋”ฐ๋ผ ํก์ธ/์„ธ์ฒ™ ๊ณผ์ •์„ 5ํšŒ ๋ฐ˜๋ณตํ•œ๋‹ค.

6

TMB Substrate: 90µl์˜ TMB Substrate๋ฅผ ๊ฐ well์— ๊ฐ€ํ•œ๋‹ค. ์ƒˆ๋กœ์šด plate sealer๋กœ ๋ฎ๋Š”๋‹ค. 37°C์—์„œ 15-20๋ถ„๊ฐ„ ๋ฐฐ์–‘ํ•œ๋‹ค. ๋น›์ด ๋‹ฟ์ง€ ์•Š๋„๋ก ํ•œ๋‹ค. ๋ฐ˜์‘์‹œ๊ฐ„์€ ์‹ค์ œ ์ƒ‰๊น” ๋ณ€ํ™”์— ๋”ฐ๋ผ ๋Š˜๋ฆฌ๊ฑฐ๋‚˜ ์ค„์ผ ์ˆ˜ ์žˆ๋Š”๋ฐ, 30๋ถ„์„ ๋„˜์ง€ ์•Š๋„๋ก ํ•œ๋‹ค. Standard well์— ๋†๋„์— ๋”ฐ๋ฅธ ์ ์ง„์ ์ธ ์ƒ‰ ๋ณ€ํ™”๊ฐ€ ๋ณด์ด๋ฉด ๋ฐ˜์‘์„ ๋๋‚ผ ์ˆ˜ ์žˆ๋‹ค.

7

์ค‘์ง€: ๊ฐ well์—50µl์˜ ์ค‘์ง€์•ก(stop solution)์„ ๋„ฃ๋Š”๋‹ค. Well์ด ์ฆ‰์‹œ ๋…ธ๋ž€์ƒ‰์œผ๋กœ ๋ณ€ํ•œ๋‹ค. ์ค‘์ง€์•ก์„ ๊ฐ€ํ•˜๋Š” ์ˆœ์„œ๋Š” substrate solution์„ ๋„ฃ์€ ์ˆœ์„œ์™€ ๋ฐ˜๋“œ์‹œ ๊ฐ™์•„์•ผ ํ•œ๋‹ค.

8

OD ์ธก์ •: 450nm๋กœ ์„ค์ •๋œ microplate reader๋ฅผ ์ด์šฉํ•˜์—ฌ, ๊ฐ well์˜ ๊ด‘ํ•™ ๋ฐ€๋„(OD Value)๋ฅผ ๋™์‹œ์— ์ธก์ •ํ•œ๋‹ค. ์ธก์ • ์ „์— ๋ฐ˜๋“œ์‹œ microplate reader๋ฅผ ์—ด๊ณ , ๊ธฐ๊ตฌ๋ฅผ ์˜ˆ์—ด์‹œํ‚ค๊ณ , ์‹คํ—˜ ๋ณ€์ˆ˜๋ฅผ ์„ค์ •ํ•ด์•ผ ํ•œ๋‹ค.